Molecular targeting is an import strategy to treat advanced colon cancer. The current study demonstrates that expression of GRM3, a metabotropic glutamate receptor mainly expressed in mammalian central nervous system, is significantly upregulated in majority of human colonic adenocarcinomas tested and colon cancer cell lines. Knockdown of GRM3 expression or inhibition of GRM3 activation in colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits tumor growth in vivo. Mechanistically, GRM3 antagonizes TGFβ-mediated activation of protein kinase A and inhibition of Protein kinase B (AKT). In addition, TGFβ signaling increases GRM3 protein stability and knockdown of GRM3 enhances TGFβ-mediated tumor suppressor function. Further studies indicate that miR-487b-3p directly targets GRM3. Overexpression of miR-487b-3p mimics the effects of GRM3 knockdown and suppresses the tumorigenicity of colon cancer cells in vivo. Expression of miR-487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3 expression. Taken together, these studies indicate that upregulation of GRM3 expression is a functionally important molecular event in colon cancer, and that GRM3 is a promising molecular target for colon cancer treatment. This is particularly interesting and important from a therapeutic standpoint because numerous metabotropic glutamate receptor antagonists are available, many of which have been found unsuitable for treatment of neuropsychiatric disorders for reasons such as inability to readily penetrate blood brain barriers. As GRM3 is upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents would not likely cause adverse neurological or peripheral side effects, making GRM3 an attractive and specific molecular target for colon cancer treatment.
INTRODUCTION
Treatment of advanced colon cancer with molecularly targeted drugs has not had large clinical impact in part due to high degree of heterogeneity. Therefore, there is a need to identify new molecule targets and develop efficient target-specific therapies.
Glutamate functions as a major excitatory neurotransmitter in mammalian central nervous system (CNS). 1, 2 Glutamate signaling is mediated by two classes of glutamate receptors, ionotropic and metabotropic receptors. 3 Metabotropic receptors (mGluR), a group C family of G-protein-coupled receptors (GPCRs), consist of eight members, classified into three subtypes. 4, 5 Group I receptors (mGluR1 and 5) are coupled to phospholipase C leading to activation of protein kinase C, whereas group II (mGluR2 and 3) and group III (mGluR4, 6, 7 and 8) receptors are negatively coupled to adenylyl cyclase, inhibiting production of cyclic AMP (cAMP). [3] [4] [5] Although glutamatergic system is mainly restricted to the CNS, expression of functional glutamate receptors has been reported in non-neuronal peripheral cells such as skin and pancreatic islets. 6, 7 Furthermore, studies have revealed that glutamate signaling is dysregulated and may have a role in cancer. [8] [9] [10] GRM3 is the gene encoding mGluR3, which is frequently mutated in melanoma. 11 Mutant GRM3 selectively activates MEK, leading to increased anchorage-independent growth and migration. 11 Activation of GRM3 has been reported to suppress bone morphogenetic protein (BMP) signaling and sustain tumorigenic potential of gliomainitiating cells. 12 Pharmacological blockade of GRM3 reduced growth of glioma cells in vitro and in vivo. [13] [14] [15] These studies suggest that GRM3 has a role in cancer and could be a potential target for cancer treatment.
Transforming growth factor β (TGFβ) signaling has a dual role in cancer. Although studies show that TGFβ promotes metastasis and is associated with worse prognosis, [16] [17] [18] [19] others demonstrate that it suppresses tumorigenicity and metastasis [20] [21] [22] [23] [24] [25] [26] and that loss or reduction of TGFβ signaling is associated with development of metastasis. 27, 28 In genetically engineered mouse models, inactivation of TGFβ signaling increases malignancy and invasiveness of intestinal tumors of Apc mutant mice. [29] [30] [31] [32] [33] MicroRNAs (miRNAs) are a group of small non-protein coding RNAs evolutionarily conserved. 34 MiRNAs suppress expression of gene targets at the post-transcriptional level through sequencespecific interaction with the 3′-untranslated regions (UTR), leading to translation inhibition or mRNA degradation. 35 Alterations in miRNA expression are found to be associated with many human cancers. 36 Here, we demonstrate that GRM3 expression is significantly upregulated in majority of human colonic adenocarcinomas tested and colon cancer cell lines. Knockdown of GRM3 expression or pharmacological blockade of GRM3 in colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits tumor growth in vivo. Mechanistically, GRM3 antagonizes TGFβ-mediated activation of protein kinase A (PKA) and inhibition of Protein kinase B (AKT) activation. In addition, TGFβ signaling increases GRM3 protein stability and knockdown of GRM3 expression enhances TGFβ-mediated tumor suppressor function. Further studies indicate that GRM3 is a direct target of miR-487b-3p and that miR-487b-3p mimics the effects of GRM3 knockdown in colon cancer cells in vitro and in vivo. Expression of miR-487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3 expression. Taken together, these studies indicate that the miR-487b-3p/GRM3/TGFβ signaling axis is an important regulator of colon cancer tumorigenesis and that upregulation of GRM3 is a functionally important molecular event in colon cancer. Therefore, GRM3 is a promising molecular target for colon cancer treatment. This is particularly interesting and important from a therapeutic standpoint because numerous metabotropic glutamate receptor antagonists are available, 37 many of which have been found unsuitable for treatment of neuropsychiatric disorders due to their inability to readily penetrate blood brain barriers. As GRM3 is upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents would not likely cause adverse neurological or peripheral side effects, making GRM3 an attractive and specific molecular target for colon cancer treatment.
RESULTS
Expression of GRM3 is markedly increased in colon cancer specimens Although it has been implicated that GRM3 is an important player in melanoma and glioma, [11] [12] [13] [14] [15] it is unknown whether GRM3 has a role in colon cancer. GRM3 expression was therefore examined in human specimens using immunohistochemistry (IHC) analysis. Verification of the anti-GRM3 antibody is shown in Figure 3c . used as a positive control. GRM3 expression was very low in normal colon epithelium, but increased significantly in colon tumors ( Figure 1a ). Quantification showed that the average intensity of GRM3 staining and percentage of GRM3-positive cells were~5.5-fold and 3.8-fold higher respectively in tumors than in normal colon (Figures 1b and c ). In addition, GRM3 expression was increased in more than 90% of colon tumors examined (Figures 1b and c) . These results demonstrate that GRM3 expression is upregulated in majority of colon adenocarcinomas. However, analysis of TCGA databases revealed that GRM3 mRNA was not increased in colon adenocarcinomas (data not shown).
GRM3 is critical for tumor growth in vivo These observations prompted us to investigate whether GRM3 has a functional role in colon cancer. A panel of human colon cancer cell lines and an immortalized human colon epithelial cell line, HCEC, 38 were used. HCT116 and RKO cells are defective in TGFβ signaling due to lack of TGFβ RII. 39 HCT116b cells were isolated from the same colon tumor as HCT116, but displayed much lower metastatic potential. 40 FET cells, isolated from a well-differentiated colon tumor, are sensitive to TGFβ-mediated growth inhibition and apoptosis. 20 CBS and GEO cells are partially responsive to TGFβ due to low TGFβ RII and RI expression, respectively. 22, 41 HT29 cells do not express Smad4 due to mutations. 42 All cell lines bear either KRAS or BRAF mutations, and all except RKO 43 have mutated APC or β-catenin. GRM3 expression was much higher in colon cancer cells than in HCECs (Figure 2a , left), consistent with the results from human specimens. However, GRM3 mRNA levels were similar between HCECs and most of colon cancer cell lines (Figure 2a , middle and right), suggesting that upregulation of GRM3 may be through post-transcriptional mechanism(s). Of note, expression of GRM2, the other member of group II metabotropic glutamate receptors, was almost undetectable in all cell lines (Figure 2a , middle). Mouse brain tissue was used as a positive control. These results indicate that expression of GRM3 but not GRM2 is increased in colon cancer cells.
To determine GRM3 function, its expression was knocked down in FET, CBS and HCT116, three colon cancer cell lines with different genetic background. Each of two independent shRNAs (sh1 and sh2) reduced GRM3 expression by more than 90% as compared with a scrambled shRNA and had no effect on GRM2 expression ( Figure 2b , data not shown). Knockdown of GRM3 increased sensitivity to growth factor deprivation stress (GFDS)-induced apoptosis, reflected by enhanced PARP cleavage ( Figure 2c ) and increased apoptosis in DNA fragmentation assays ( Figure 2d ). In addition, GRM3 knockdown decreased anchorage-independent growth (Figure 2e ; Supplementary Figure S1a and b) and inhibited motility and migration ( Figure 2f ). We next examined the effect of GRM3 knockdown in vivo. Mice were subcutaneously injected with CBS cells stably expressing a scrambled shRNA or GRM3 shRNAs. Xenograft tumor growth curves showed that tumors of GRM3 shRNA-expressing cells (designated GRM3 shRNA tumors) grew at a significantly lower rate than those of control cells (designated control tumors) ( Figure 3a ). As a result, GRM3 shRNA tumors were much smaller than control tumors (Figure 3b ). IHC staining confirmed GRM3 knockdown in GRM3 shRNA tumors and verified the specificity of the anti-GRM3 antibody (Figure 3c ). TUNEL and Ki67 staining showed much more apoptotic cells and fewer proliferative cells in GRM3 shRNA tumors than in control tumors ( Figure 3d ). These results indicate that knockdown of GRM3 inhibits tumor growth in vivo and that this inhibitory effect is a combined result of increased apoptosis and suppressed proliferation.
A GRM3 antagonist mimics GRM3 knockdown in vitro and in vivo LY341495 is a potent and selective antagonist of GRM2/3. 44 As shown in Figure 4a and Supplementary Figure S1c, LY341495 reduced colony formation of HCT116 cells in soft agar. When mice subcutaneously injected with HCT116 cells were treated with LY341495, tumors grew at a slower rate than those treated with vehicle control (Figure 4b ). Therefore, tumors were markedly smaller in LY341495-treated group than in control group (Figure 4c ). TUNEL and Ki67 staining showed that LY341495 increased apoptotic cells and decreased proliferative cells ( Figure 4d ). These results indicate that pharmacological blockade of GRM3 reduces anchorage-independent growth in vitro and tumor growth in vivo.
GRM3 antagonizes TGFβ to regulate cell survival through the PKA/AKT signaling axis GRM3 is negatively coupled to adenylyl cyclase, inhibiting production of cAMP. [3] [4] [5] As cAMP activates PKA, 45 which inhibits AKT activation, 23 activation of PKA and AKT was determined. PKA activity assays showed that knockdown of GRM3 increased PKA activity ( Figure 5a ). Phosphorylation of CREB, a target of PKA, 45 was also used to indicate PKA activity. Knockdown of GRM3 increased pCREB and decreased pAKT ( Figure 5b , left and Figure 5c ). Treatment with LY341495 or forskolin, a PKA activator, showed similar effect (Figure 5b , middle). Complementarily, overexpression of GRM3 reduced pCREB and increased pAKT (Figure 5b , right). These results indicate that GRM3 inhibits PKA and activates AKT in colon cancer cells.
To determine whether PKA is involved in GRM3-mediated cell survival, the PKA catalytic α subunit (PKACα) was knocked down in FET cells. 46 increase of apoptosis under GFDS ( Figure 5e ). These results indicate that GRM3 knockdown inhibits AKT and suppresses cell survival through PKA activation. Unlike GRM3's coupling to cAMP, [3] [4] [5] TGFβ activates PKA independent of cAMP, which inhibits AKT and suppresses cell survival. 23 We confirmed TGFβ effect on pCREB and pAKT in FET cells (Figure 5d , left). As GRM3 knockdown and TGFβ activate PKA independently, we determined whether combination of both would further activate PKA and inhibit AKT. The results showed that GRM3 knockdown and TGFβ treatment concomitantly led to additional increase in pCREB and decrease in pAKT (Figure 5d , left). As a result, when cells were treated with TGFβ under GFDS for 14 hours, TGFβ had little effect in control cells but induced apoptosis in GRM3 knockdown cells (Figure 5f ). In addition, GRM3 knockdown sensitized FET cells to TGFβ-mediated inhibition of anchorage-independent growth (Figure 5g ; Supplementary Figure S1a ). These results indicate that GRM3 antagonizes TGFβmediated tumor suppressor function and that GRM3 knockdown enhances TGFβ effects.
To determine the mechanism underlying collaborative effect of TGFβ and GRM3 knockdown on PKA/AKT activation, cell survival and anchorage-independent growth, we investigated whether GRM3 mediates TGFβ signaling and found that GRM3 knockdown had no effect on expression of Smad2, Smad3, Smad4 or on canonical TGFβ signaling (data not shown). However, TGFβ increased GRM3 protein expression in FET and CBS cells ( MiR-487b-3p regulates GRM3 expression in colon cancer cells Although TGFβ increases GRM3 expression ( Figure 5h ), it cannot fully explain ubiquitous upregulation of GRM3 expression in colon cancer cell lines regardless of their response to TGFβ signaling (Figure 2a, left) . As GRM3 expression may be regulated post-transcriptionally (Figure 2a ), we turned our attention to miRNAs, which function as post-transcriptional regulators of mRNA expression and/or translation. 35 We performed an in silico search for putative miRNA-binding sites in the 3′UTR of human GRM3 mRNA using TargetScan, 47 PicTar 48 and miRanda-mirSVR. 49 Among miRNA candidates conserved between human and mouse, miR-487b-3p was identified as a potential regulator of GRM3. GRM3 antagonizes TGFβ in colon cancer tumorigenesis H Yi et al Q-PCR assays indicated that expression of miR-487b-3p was much lower in colon cancer cell lines than in HCECs (Figure 6a ), suggesting that decreased miR-487b-3p expression may contribute to upregulated GRM3 expression in colon cancer cells.
To demonstrate that miR-487b-3p regulates GRM3 expression, miR-487b precursor was stably infected into FET and CBS cells. As a result, expression of mature miR-487b-3p was significantly increased (Figure 6b, left) . Complementarily, a chemically synthesized miR-487b-3p inhibitor markedly reduced endogenous miR-487b-3p expression (Figure 6b, right) . Overexpression of miR-487b-3p decreased GRM3 protein expression whereas the inhibitor increased GRM3 protein expression (Figure 6c, left) . However, GRM3 mRNA expression was not affected (Figure 6c,  right) . These results indicate that miR-487b-3p suppresses GRM3 expression by inhibiting its translation. To determine whether GRM3 is a direct target of miR-487b-3p, 3′-UTRs of GRM3 containing potential miR-487b-3p recognition element or mutated seed sequence (Figure 6d , left) was cloned into a luciferase construct. Luciferase assays revealed that miR-487b-3p repressed wild type but not mutant 3′-UTRs of GRM3 (Figure 6d, right) . These results indicate that GRM3 is a direct target of miR-487b-3p. Of note, miR-487b-5p did not target GRM3 (Supplementary Figure S2 ).
MiR-487b-3p regulates PKA/AKT activation and mimics GRM3 knockdown effect in colon cancer cells
Similar to GRM3 knockdown, miR-487b-3p enhanced PKA activity (Figure 6e ), increased pCREB and decreased pAKT (Figure 6f ). MiR-487b-3p-expressing cells displayed increased apoptosis under GFDS (Figure 6g ) and decreased anchorage-independent growth (Figure 6h; Supplementary Figure S3 ), indicating that miR-487b-3p mimicked the effect of GRM3 knockdown. In contrast, the miR-487b-3p inhibitor decreased GFDS-induced apoptosis (Figure 6i ).
To determine whether miR-487b-3p-mediated effect could be reversed by restoration of GRM3 expression, GRM3 cDNA was infected into miR-487b-3p-expressing cells (Figure 6j ). Ectopically expressed GRM3 is resistant to miR-487b-3p inhibition due to the lack of 3′-UTR. Restored GRM3 expression reversed miR-487b-3pmediated increase of apoptosis (Figure 6k ). These results indicate that miR-487b-3p sensitizes colon cancer cells to GFDS-induced apoptosis through down-regulation of GRM3.
To demonstrate that miR-487b-3p enhances TGFβ-mediated tumor suppressor function, FET cells were treated with TGFβ under GFDS for 14 hours. TGFβ induced apoptosis in miR-487b-3pexpressing cells but not in control cells (Figure 7a ). In addition, TGFβ inhibited anchorage-independent growth by 96% in miR-487b-3p-expressing cells but only by 50% in control cells (Figure 7b; Supplementary Figure S3a ). Restoration of GRM3 expression reversed miR-487b-3p-mediated sensitization to TGFβinduced apoptosis (Figure 7c ). Complementarily, FET cells were treated with TGFβ under GFDS for 24 hours. Although TGFβ-induced apoptosis in control cells, the miR-487b-3p inhibitor attenuated TGFβ-induced apoptosis (Figure 7d ). These results indicated that miR-487b-3p enhances TGFβ-induced apoptosis by repressing GRM3 expression and that inhibition of miR-487b-3p antagonizes TGFβ effect. Of note, TGFβ does not regulate miR-487b-3p expression (data not shown).
MiR-487b-3p inhibits tumor growth in vivo
To determine the function of miR-487b-3p in vivo, athymic nude mice were subcutaneously inoculated with CBS control or miR-487b-3p-expressing cells. Xenograft tumor growth curves indicated that tumors of control cells (designated control tumors) grew at a significantly higher rate than those of miR-487b-3pexpressing cells (designated miR-487b-3p tumors; Figure 8a ). Consequently, control tumors were much bigger than miR-487b-3p tumors (Figure 8b ). Analysis of GRM3 expression showed that the intensity of GRM3 staining and percentage of GRM3-positive cells were notably lower in miR-487b-3p tumors than in control tumors (Figure 8c ). Moreover, TUNEL and Ki67 staining indicated more apoptotic cells and fewer proliferative cells in miR-487b-3p tumors than in control tumors (Figures 8d and e ). These results demonstrate that miR-487b-3p suppresses GRM3 expression and inhibit tumor growth in vivo.
Expression of miR-487b-3p is decreased in colon cancer specimens
To explore clinical relevance of miR-487b-3p, its expression was determined by in situ hybridization in the same sets of TMAs utilized in Figure 1 . The staining intensity of miR-487b-3p was much stronger in miR-487b-3p-expressing tumors than in control tumors (Figure 9a ), verifying the specificity of the probe. Analysis of TMAs indicated that miR-487b-3p expression was very high in normal colon epithelium, but decreased markedly in colon tumors (Figure 9b ). Quantification of staining showed that the average intensity was significantly lower in colon adenocarcinomas than in normal colon (Figure 9c ), which is consistent with results from TCGA databases (Supplementary Figure S4 ). In addition, the correlation study revealed a significant inverse correlation between miR-487b-3p and GRM3 expression ( Figure 9d , ***P = 0.0003). These results demonstrate that miR-487b-3p expression is decreased in colon adenocarcinomas and that miR-487b-3p expression is inversely correlated with GRM3 expression.
Taken together, our studies suggest a novel model of crosstalk between m1iR-487b-3p, GRM3 and TGFβ signaling (Figure 8f ). In this model, although miR-487b-3p inhibits GRM3 translation, TGFβ increases GRM3 protein stability as a negative feedback mechanism to antagonize TGFβ-induced PKA activation, AKT inhibition and suppression of cell survival, proliferation and tumorigenesis. Therefore, inhibition of GRM3 or expression of miR-487b-3p prevents this negative feedback and enhances TGFβ-mediated tumor suppressor function. 
DISCUSSION
Although GRM3 protein expression is considerably higher in colon adenocarcinomas than in normal colon (Figure 1 ), analysis of TCGA databases reveals that GRM3 mRNA remains unchanged (data not shown). It suggests that GRM3 upregulation is mediated at the post-transcriptional level. Although transcriptional regulation of GRM3 has been reported, [50] [51] [52] [53] our findings that miR-487b-3p directly targets GRM3 to suppress its translation and that TGFβ increases GRM3 protein stability provide novel mechanisms of post-transcriptional regulation of GRM3 in colon cancer. Of note, GRM2, the other group II metabotropic glutamate receptor, and GRM4, reported to be present in colon cancer cells, 8 are barely expressed in colon cancer cells used in the study (Figure 2a ; Supplementary Figure S5 ), suggesting that they may not have a role in colon cancer.
When correlating GRM3 expression with clinicopathological features of tumors, no significant correlation was found between GRM3 expression and tumor grades or stages (data not shown). However, percentage of GRM3-positive cells is noticeably higher in poorly-differentiated tumors than moderately-differentiated ones (Supplementary Figure S6a) . Owing to the small sample size of well-differentiated tumors, the difference between welldifferentiated tumors and moderately-or poor-differentiated ones is not significant. In addition, GRM3 expression is significantly higher in pancreatic tumors than in normal pancreas (Supplementary Figures S6b and c) , indicating that upregulation of GRM3 expression is not specific to colon cancer.
It has been shown that mGluRs, such as GRM1 and mutant GRM3, activate the MEK pathway in nervous and melanoma cells. 9, 11 In this study, we show that GRM3 knockdown activates PKA and inhibits AKT in colon cancer cells. In addition, GRM3 knockdown or overexpression of miR-487b-3p also decreases ERK activity (Supplementary Figure S7 ). It indicates that GRM3 can activate multiple cancer-related signaling pathways and that the components of the glutamatergic system are active in colon cancer cells. Although we show that GRM2 expression is not upregulated in colon cancer cells, it remains to be determined whether other glutamate receptors or other elements of glutamate signaling are aberrantly expressed in colon cancer.
Our studies indicate that GRM3 antagonizes TGFβ-mediated tumor suppressor effect and that TGFβ increases GRM3 protein stability in a Smad2/3-dependent manner. These results suggest that there is a negative feedback regulation between GRM3 and TGFβ signaling (Figure 8f ). This is of significance as TGFβ is a major tumor suppressor in colon cancer. 21, 22, 39, 41 The negative feedback regulation between TGFβ and GRM3 could potentially prevent efficient intervention of tumor growth and progression by TGFβ signaling. In addition, it will be interesting to investigate whether TGFβ increases GRM3 expression in cancers where TGFβ functions as a tumor promoter (that is, breast cancer). If so, given that GRM3 activates AKT and MEK signaling pathways, GRM3 could potentially contribute to TGFβ-mediated tumor promoting function (that is, EMT and so on). Therefore, inhibition of GRM3 could not only enhance TGFβ-mediated tumor suppressor function but also counteract TGFβ-mediated tumor promoting function, making targeting GRM3 an efficient anti-cancer approach despite of dual function of TGFβ signaling. Furthermore, GRM3 can also function independently of TGFβ signaling as GRM3 knockdown in HCT116 cells with defective TGFβ signaling increased apoptosis and reduced anchorage-independent growth (Figure 2 ). Hence, GRM3 can be a promising molecular target in colon cancer defective of TGFβ signaling, which occurs in 30-40% of colon cancer patients. It has been reported that GRM3 negatively regulates BMP signaling in glioma cells. 12 However, we found that GRM3 knockdown did not activate BMP signaling in colon cancer cells (Supplementary Figure S8a ). In addition, unlike TGFβ, BMP treatment did not increase GRM3 expression (Supplementary Figure S8b) . These results suggest that BMP signaling is not likely involved in the effects mediated by GRM3 knockdown and in the regulation of GRM3 expression.
Taken together, we have identified a signaling axis, miR-487b-3p/ GRM3/TGFβ/PKA/AKT, as an important regulator of tumorigenesis in colon cancer. Our studies suggest that GRM3 could be a novel molecular target for colon cancer treatment. However, one concern to target glutamate signaling for cancer treatment is whether it would affect brain or neuron function. A significant amount of work has gone into designing and testing of drugs to modulate glutamatergic system to treat neurological and psychiatric disorders. Pharmaceutical companies have generated libraries of compounds that are not optimal for treating neuropsychiatric disorders due to problems such as inability to readily penetrate blood brain barriers. However, those compounds could be ideal agents for other applications, for example, anti-cancer therapy. As GRM3 is mainly upregulated in colon cancer but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents would not likely cause adverse neurological or peripheral side effects, making GRM3 an attractive and specific target for colon cancer treatment.
MATERIALS AND METHODS

Cell lines and reagents
The immortalized human colon epithelial cells (HCEC) were provided by Dr. Jerry Shay. 38 The human colon cancer HCT116, RKO, FET, CBS, HCT116b, GEO and HT29 cells were cultured in McCoy's 5A medium (Sigma, St Louis, MO, USA) with 10 ng/ml epidermal growth factor (EGF), 20 μg/ml insulin and 4 μg/ml transferrin. 54 When subjected to GFDS, cells were cultured in medium without EGF, insulin and transferrin. Cells were maintained at 37°C in a humidified incubator with 5% CO 2 and checked periodically for mycoplasma contamination. TGFβ, LY341495 and miR-487b-3p inhibitor were obtained from R&D Systems (Minneapolis, MN, USA), Cayman (Ann Arbor, MI, USA) and Qiagen (Hilden, Germany), respectively. Antibodies for western blot or IHC analyses were described in Supplementary Table 1 .
RT-PCR and Q-PCR assays
Expression of miR-487b-3p was determined by miScript primer assays and miScript SYBR Green PCR Kit from Qiagen. RNU6-2 was used as an endogenous reference gene. Q-PCR analysis of GRM3 mRNA was performed using SYBR Green qPCR Mastermixes (Qiagen). The primer sequences are GCACCTCAACAGGTTCAGTGT-F and TGGTGGAGTCGAGGACTTCC-R.
RT-PCR analysis of GRM2 and GRM3 mRNA was performed using primers GRM2, GAGAAGGTGGGCCGTGCCATGAG-F and CGCTGCCTGCCCGCAGATAGGT-R and GRM3, GCTCCAACATCCGCAAGTCCTA-F and TGTCAATGGCCAGGTG CTTGTC-R.
Apoptosis assays
Apoptosis was detected using a DNA fragmentation ELISA assay kit (Roche, Basel, Switzerland) according to manufacturer's protocol. Briefly, cells were seeded in 96-well plates and subjected to GFDS and/or treated with TGFβ. The cells were stained with MTT to determine cell numbers or lysed for ELISA assays to determine apoptosis. The relative apoptosis was determined by dividing ELISA values by MTT values of each sample.
Soft agarose assays
Cells were seeded in medium containing low melting agar (Thermo Scientific, Waltham, MA, USA) at 3000 cells per well in 6-well plates. Two weeks later, colonies were stained with 1% iodonitrotetrazolium violet (Sigma-Aldrich, St Louis, MO, USA) and counted. 
Transwell assays
Cells were seeded onto the upper surface of 8-μm pore, 6.5 mm polycarbonate filters (Corning Costar, Corning, NY, USA) in medium without growth factors or serum, allowed to migrate towards medium with 10% FBS for 18 h and stained with MTT. The cells on the upper surface of the filter were removed with a cotton swab, and those migrated to the underside were dissolved in DMSO. Absorbance was read at 570 nm.
Plasmids construction
The miR-487b precursor-expressing lentiviral vector, pCDH-CMV, was from SBI. ShRNAs targeting GRM3 were cloned into FSIPPW lentiviral vector. The targeting sequences of GRM3 were: sh1, 5′-CAGAACATGGAAATAACCATT-3′ and sh2, 5′-GCCTGTTTCCTATTAACGAAA-3′. 11 ShRNAs for Smad2 and Smad3 are 5′-GCACTTGCTCTGAAATTTG-3′ and 5′-GGATTGAGCTGCACCTTG AATG-3′, respectively. PKACα shRNA was described previously. 23 pCDF1-GRM3 was a gift from Yardena Samuels (Addgene, Cambridge, MA, USA; #31798).
Luciferase assays
The predicted miR-487b-3p recognition site in the 3′UTR of GRM3 and corresponding mutated sequences were synthesized and cloned into psiCHECK-2 (Promega, Madison, WI, USA) downstream of Renilla reporter gene. The reporter was transfected into cells and luciferase activity was measured 48 h later using Dual-Luciferase Reporter Assay (Promega). Values were normalized with firefly luciferase activity.
PKA assays
Kinase activity of PKA was measured with DetectX PKA activity kit (Arbor assays, Ann Arbor, MI, USA) following manufactory's protocol.
In vivo xenograft model
Animal experiments were approved by University of Nebraska Medical Center (UNMC) Institutional Animal Care and Use Committee. CBS cells (4 × 10 6 ) expressing a control vector, miR-487b precursor, a scrambled shRNA or GRM3 shRNAs were injected into the flank of 4-6 week old male athymic nude mice on both sides (Harlan Laboratories, Indianapolis, IN, USA). In addition, mice injected with HCT116 cells (2 × 10 6 ) were treated with 10 mg/kg LY341495 (dissolved in 1.2 e.q. NaOH) by subcutaneous injection every day for 10 days. There were 7-8 mice and 14-16 tumors in each experimental group. Tumor volumes (V) were calculated by the formula V = W 2 × L × 0.5, where W represents the largest tumor diameter and L represents the next largest tumor diameter. 55, 56 On termination of the experiments, tumors were dissected out and photographed on the same scale.
TUNEL and Ki67 staining
Formalin-fixed paraffin embedded tissue blocks of xenograft tumors were stained for TUNEL and Ki67 as described previously. 34, 35 IHC staining of GRM3 in xenograft tumors and human patient samples Human sample study was performed with the approval of Institutional Review Board. TMAs consisting of triplicates of 1 mm cores of 65 colon adenocarcinomas and 29 adjacent normal tissues of patients treated at UNMC in 2008 and 2009 were obtained from tissue core. IHC staining was performed in paraffin slides using Novolink Min Polymer Detection System (Leica, Wetzlar, Hesse, Germany) as described previously. 56, 57 Briefly, slides were subjected to antigen retrieval using Novocastra Epitope Retrieval Solutions (Leica), pH6, followed by incubation with an anti-GRM3 antibody overnight at 4°C. Slides were developed with DAB after incubation with Novolink polymer (Leica). Finally, slides were counterstained with hematoxylin. For each sample, ten randomly chosen fields were captured at × 40 magnification and quantified with Imagescope Software (Aperio Technologies, Vista, CA, USA).
